Ionomycin calcium salt |
| Catalog No.GC15148 |
Ionomycin calcium salt is a narrow spectrum antibiotic being active against Gram-positive bacteria, which produced by the bacterium Streptomyces conglobatus.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 56092-82-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Ionomycin calcium salt is a narrow spectrum antibiotic being active against Gram-positive bacteria, which produced by the bacterium Streptomyces conglobatus[1]. Ionomycin calcium salt promotes apoptosis. Ionomycin also induces the activation of protein kinase C (PKC)[2].
In vitro, treatment with 2 µM Ionomycin in LCLC 103H cells results in an instantaneous increase in intracellular Ca2+ concentration from 50 to 180 nM. And in Ionomycin-treated cultures, there is obvious DNA fragmentation and PARP cleavage to an 85-kDa fragment, and necrosis could be detected in ~1-5% of the Ionomycin treated cells[2]. In ras oncogene expressing cells, Ionomycin leads to a dose dependent increase of intracellular calcium activity. At 100 nmol/l ionomycin intracellular calcium is increased from 114 ± 17 nmol/l to 342 ± 24 nmol/l, a value within the range of intracellular calcium concentrations following application of bradykinin[3].
In vivo efficacy test, treatment with 1 µm ionomycin for 6 h, ubiquitination of ENaC-β was robustly enhanced in cells overexpressing wild-type Nedd4-2a[4].
References:
[1] Liu WC, et al. Ionomycin, a new polyether antibiotic. J Antibiot (Tokyo). 1978 Sep;31(9):815-9.
[2] Chatila T, et al. Mechanisms of T cell activation by the calcium ionophore ionomycin. J Immunol. 1989 Aug 15;143(4):1283-9.
[3] WÖll E, et al. The role of calcium in cell shrinkage and intracellular alkalinization by bradykinin in Ha-ras oncogene expressing cells. FEBS Lett. 1993 May 17;322(3):261-5.
[4] Wang J, et al. Calcium activates Nedd4 E3 ubiquitin ligases by releasing the C2 domain-mediated auto-inhibition. J Biol Chem. 2010 Apr 16;285(16):12279-88.
| Cell experiment [1]: | |
|
Cell lines |
N1E-115 cells |
|
Preparation Method |
Cells were treated with various concentrations (0, 0.2, 0.5, 1, 2, and 10 µM) and incubation times (3, 6, 12, and 24 h) of ionomycin, and cell survival was determined using the trypan blue dye exclusion assay. |
|
Reaction Conditions |
0, 0.2, 0.5, 1, 2, and 10 µM；3, 6, 12, and 24 h |
|
Applications |
Ionomycin treatment induced cell death in a concentration- and time-dependent manner. |
| Animal experiment [2]: | |
|
Animal models |
Adult male C57BL/6 wild type (20-25 g, 8-10 weeks old) and FXR KO mice (20-25 g, 8-10 weeks old) |
|
Preparation Method |
In order to investigate the biological function of FXR in vivo, an L-type calcium channel agonist, Bayk8644 (2 mg/kg) was given intraperitoneally at 10 min after reperfusion. Bayk8644 stock solution (1 mmol/L in dimethyl sulfoxide, DMSO) was diluted in 1× phosphate-buffered saline (PBS) with a final DMSO concentration of 4.6%. Similarly, PBS with 4.6% DMSO was given intraperitoneally in sham, wild-type vehicle, and FXR knockout vehicle groups as control. A dose range of ionomycin (50 nmol/L), GW4064 (0, 1, 1.5, 3, and 6 µmol/L), or Z-guggulsterone (Z-GS, 0, 2.5, 5, and 10 µmol/L) was given for 18 h before oxygen and glucose deprivation (OGD). |
|
Dosage form |
50 nmol/L (4.6% DMSO); 18 h; i.p. |
|
Applications |
TUNEL staining demonstrated that Z-GS treatment reduced neuronal apoptosis and addition of IM (Ionomycin) significantly increased apoptotic neurons compared to OGD group, suggesting that inhibition of FXR (Farnesoid X receptor) can reduce neuronal apoptosis through reducing calcium influx after OGD/R. |
|
References: Nakamura S, et al. Ionomycin-induced calcium influx induces neurite degeneration in mouse neuroblastoma cells: analysis of a time-lapse live cell imaging system. Free Radic Res. 2016;50(11):1214-1225. |
|
| Cas No. | 56092-82-1 | SDF | |
| Chemical Name | calcium (4S,6S,8S,10E,12R,14R,16E,18S,19S,20R,21S)-19,21-dihydroxy-22-((2R,2'R,5R,5'S)-5'-((R)-1-hydroxyethyl)-2,5'-dimethyloctahydro-[2,2'-bifuran]-5-yl)-4,6,8,12,14,18,20-heptamethyl-11-oxido-9-oxodocosa-10,16-dienoate | ||
| Canonical SMILES | O[C@H](C)[C@@]1(C)O[C@H](CC1)[C@]2(C)O[C@@H](C[C@@H]([C@@H](C)[C@H]([C@H](/C=C/C[C@@H](C)C[C@@H](C)/C([O-])=C\C([C@@H](C)C[C@@H](C)C[C@@H](C)CCC([O-])=O)=O)C)O)O)CC2.[Ca+2] | ||
| Formula | C41H70O9.Ca | M.Wt | 747.08 |
| Solubility | 20mg/mL in enathol, 1.6mg/mL in DMSO, 1.2mg/mL in DMF | Storage | Store at -20°C,protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.3385 mL | 6.6927 mL | 13.3854 mL |
| 5 mM | 0.2677 mL | 1.3385 mL | 2.6771 mL |
| 10 mM | 0.1339 mL | 0.6693 mL | 1.3385 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 3 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *